Alan Garen, professor of molecular biophysics and biochemistry at Yale has received a $100,000 award from the Prostate Cancer Foundation to expand research on the delivery of a targeted therapy for prostate cancer using nanoparticles.
Women with a recent diagnosis of cancer in one breast should have MRI screening of the opposite breast, concludes a multi-center study involving University of North Carolina at Chapel Hill researchers.
Long waits for endoscopies have been eliminated in many parts of the UK, but some people are still waiting too long for the procedures, particularly in the south east, according to a report published by the Healthcare Commission, UK.
Obese and overweight men who are diagnosed with prostate cancer by biopsy are more likely than healthy weight men to actually have a more aggressive case of the disease than the biopsy results would indicate, according to a study led by a Duke University Medical Center researcher.
The University of Texas M. D. Anderson Cancer Center has joined the U.S.-Middle East Partnership for Breast Cancer Awareness and Research, a collaboration designed to increase early breast cancer detection and reduce related deaths in the region through improved awareness, increased clinical resources and world-class research.
If you want the best technology available to relieve blocked blood flow to the heart, the choice is a drug-eluting stent. And you are most likely to obtain the drug-eluting stent for reasons that have nothing to do with your medical condition, a new Mayo Clinic study shows.
In an era of increasing death and illness from heart and blood vessel disease — which also can impair kidney function — Mayo Clinic researchers have designed two promising new cardiovascular treatment approaches.
An herbal medicinal substance, Crataegus Extract WS?1442, safely extends the lives of congestive heart failure patients already receiving pharmacological treatment for the disease, according to a study presented today at the American College of Cardiology?s 56th Annual Scientific Session.
Researchers today reported that an investigational anti-hypertensive therapy may perform better in controlling blood pressure than standard treatments for patients undergoing heart surgery, during a presentation at the American College of Cardiology?s 56th Annual Scientific Session.
Chest pain due to a shortage of blood in the heart, known as angina, is a condition that affects millions of Americans. The most recently approved new pharmaceutical approach to treat chronic angina is a novel drug called ranolazine, which was approved in 2006 for use as second line therapy in patients who continue to experience angina despite treatment with another class of anti-anginal medication.